Executive Order on Agricultural Biotechnology Is an Important Step Forward

During his June 11th visit to Iowa, President Donald Trump pledged to boost the ethanol industry and protect farmers. Specifically, the president lifted a summertime ban on E15 gasoline blends and then signed an executive order to streamline the process for approving products of agricultural biotechnology.

Spotlight

Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc. s a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,

OTHER ARTICLES
MedTech

Immunology: A New Frontier in Medical Science

Article | July 13, 2022

Introduction Recent developments in the bioengineering of monoclonal antibodies (mAbs) have revolutionized the treatment of numerous rheumatic and immunological disorders. Currently, several immunological disorders are successfully being targeted and treated using innovative medical techniques such as immunotherapy. Leading companies are increasingly investing in research activities to expand the usage and application of immunology for the treatment of various infectious diseases, including multiple sclerosis, inflammatory bowel disorders, lupus, and psoriasis, leading companies are increasingly investing in research activities. Today, the efforts of researchers in immunology, with a long history of study and research, have borne fruit, as bioengineered mAbs are now being employed in clinical practices. Accelerating Investments: Paving the Way for Immunology The increasing prevalence of infectious diseases, cancer, and immune-mediated inflammatory disorders (IMIDs) is raising the need for more precise classification and an in-depth understanding of the pathology underlying these ailments. Numerous leaders in the biotechnology domain are thus focusing on undertaking numerous strategies, such as new facility launches and collaborations, to address the need by finding deeper inroads into immunology and its use in disease treatments. For instance, in 2022, the University of Texas MD Anderson Cancer Center announced the launch of a visionary research and innovation hub, the James P. Allison Institute, to find new roads in immunotherapy, develop new treatments, and foster groundbreaking science. These developments will result in better diagnosis through the use of selective biomarkers, and early detection of fatal diseases and their treatment, which will prevent complications from happening. Also, the identification of high-risk populations through a deeper understanding of genetic and environmental factors can assist in the prevention of disease through immunotherapy. The Way Forward Immunology has led to the development of biotechnology, making it possible to develop novel drugs and vaccines, as well as diagnostic tests, that can be used to prevent, diagnose, and treat a wide range of autoimmune, infectious, and cancerous diseases. With the rapid advancement in technology and the integration of artificial intelligence, immunology is finding its way into an array of domains and industries, encompassing several research areas including medicine, pharmaceuticals, agriculture, and space. Today, not only researchers but also leading biotech and pharmaceutical companies have recognized that conventional therapies with pharmaceutical and chemical products are being replaced by products derived from immunology. This is because they work well for health problems, are environmentally friendly, and are also emerging as a wealth-generating business in the medical field.

Read More
MedTech

5 Biotech Stocks Winning the Coronavirus Race

Article | July 11, 2022

There are quite a few companies that have found ways to grow their business during the ongoing COVID-19 pandemic. This is especially true for a number of biotechs now working on developing a potential treatment for, or vaccine against, the virus; shares of such companies have largely surged over the past couple of months. Although many of these treatments and vaccines are still have quite a way to go before they're widely available, it's still worth taking some time to look through what's going on in the COVID-19 space right now. Here are five biotech stocks that are leading the way when it comes to addressing COVID-19. Regeneron Pharmaceuticals (NASDAQ:REGN) wasn't among the initial wave of companies to announce a potential COVID-19 drug. However, investor excitement quickly sent shares surging when the company announced that its rheumatoid arthritis drug, Kevzara, could help treat COVID-19 patients.

Read More
Medical

2 Small-Cap Biotech Stocks You Haven't Heard of, But Should Know About

Article | August 16, 2022

With everything that's going on with the COVID-19 pandemic, many healthcare companies have grabbed plenty of spotlight during these challenging times. At the same time, a number of otherwise promising businesses have slipped under the radar. That's especially true for small-cap biotech stocks that aren't actively involved in developing tests, vaccines or treatments for COVID-19. Vaccine developers, protective equipment producers, and healthcare service providers are all attracting plenty of attention during this pandemic, but there are just as many promising biotech stocks that aren't involved in these areas. Here are two such companies that you might have missed, but they deserve a spot on your watch list.

Read More
MedTech

Next-Gen Genetics Cancer Therapies Creating Investment Prospects

Article | July 5, 2022

Genetic therapeutics such as genetic engineering and gene therapy are increasingly emerging as one of the most influential and transformed biotechnological solutions around the globe in recent times. These genetic solutions are being assessed across various medical domains, including cancer treatment, neurology, oncology, and ophthalmology. Citing the trend, the genetics industry is estimated to experience a tsunami of approvals, with over 1,000 cell and gene therapy clinical trials currently underway and over 900 companies worldwide focusing on these cutting-edge therapies. Growing Cancer Encourages Advancements in Genetic Technologies With the surging cases of cancers such as leukemias, carcinomas, lymphomas, and others, patients worldwide are increasing their spending on adopting novel therapeutic solutions for non-recurring treatment of the disease, such as gene therapy, genetic engineering, T-cell therapy, and gene editing. As per a study by the Fight Cancer Organization, spending on the treatment of cancer increased to $200.7 billion, and the amount is anticipated to exceed $245 billion by the end of 2030. Growing revenue prospects are encouraging biotechnology and biopharmaceutical companies to develop novel genetic solutions for cancer treatment. For instance, Bristol-Myers Squibb K.K., a Japanese pharmaceutical company, introduced a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, Abecma, for the treatment of relapsed or refractory (R/R) multiple myeloma in 2022. Amid a New Market: Genetics Will Attract Massive Investments Despite several developments and technological advancements, genetics is still considered to be in a nascent stage, providing significant prospects for growth to the companies that are already operating in the domain. Genetics solutions such as gene therapies, gene editing, and T-cell immunotherapy are emerging as highly active treatments across various medical fields, resulting in increasing research and development activities across the domain, drawing significant attention from investors. Given the potential of genetic treatments and the focus on finding new ways to treat cancer and other related diseases, it's easy to understand why companies are investing in the domain. For instance, Pfizer has recently announced an investment of around $800 million to construct development facilities supporting gene therapy manufacturing from initial preclinical research through final commercial-scale production. Due to these advancements, cell and gene therapies are forecast to grow from $4 billion annually to more than $45 billion, exhibiting growth at a 63% CAGR. The Future of Genetics Though there is a significant rise in advancement in genetic technologies and developments, the number of approved genetic treatments remains extremely small. However, with gene transfer and CRISPR solutions emerging as new modalities for cancer treatment, the start-up companies will attract a growing amount and proportion of private and public investments. This is expected present a tremendous opportunity for biopharma and biotechnology investors to help fund and benefit from the medical industry's shift from traditional treatments to cutting-edge genetic therapeutics in the coming years.

Read More

Spotlight

Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc. s a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,

Related News

Agricultural Biotechnology Market Size, Share, Analysis, Report and forecast to 2022

biotech | March 06, 2017

According to Stratistics MRC, the Global Agricultural Biotechnology market is accounted for $20.08 billion in 2015 and is expected to reach $39.5 billion by 2022 growing at a CAGR of 10.1% from 2015 to 2022. Factors stimulating the market growth are increasing demand for food, growing area of biotech crops, rising demand for biofuels & bio plastic production and demand for animal feed. Furthermore, increased investments and capital inflow for industry participants and research & development within Africa and Asia Pacific region will provide more growth prospects towards the market.

Read More

Agricultural biotechnology crucial for feeding world population

biotech | January 31, 2017

Sarnia - It took until 1800 for the world population to reach one billion people. The second billion was reached in only 130 years (1930), the third billion in less than 30 years (1959), the fourth billion in 15 years (1974) and the fifth billion in only 13 years (1987). During the 20th century alone, the global population grew from 1.6 billion to over six billion people.

Read More

Agricultural Biotechnology Market Size, Share, Analysis, Report and forecast to 2022

biotech | March 06, 2017

According to Stratistics MRC, the Global Agricultural Biotechnology market is accounted for $20.08 billion in 2015 and is expected to reach $39.5 billion by 2022 growing at a CAGR of 10.1% from 2015 to 2022. Factors stimulating the market growth are increasing demand for food, growing area of biotech crops, rising demand for biofuels & bio plastic production and demand for animal feed. Furthermore, increased investments and capital inflow for industry participants and research & development within Africa and Asia Pacific region will provide more growth prospects towards the market.

Read More

Agricultural biotechnology crucial for feeding world population

biotech | January 31, 2017

Sarnia - It took until 1800 for the world population to reach one billion people. The second billion was reached in only 130 years (1930), the third billion in less than 30 years (1959), the fourth billion in 15 years (1974) and the fifth billion in only 13 years (1987). During the 20th century alone, the global population grew from 1.6 billion to over six billion people.

Read More

Events